Key result
Bay a 1040 ( daily) demonstrated outstanding preventive efficacy on the occurrence of anginal attacks in patients with ischemic heart disease.
Why the study?
Does Bay a 1040 improve hemodynamics and prevent anginal attacks in dogs and patients with ischemic heart disease?
RCT
Cross-over
Does Bay a 1040 improve hemodynamics and prevent anginal attacks in dogs and patients with ischemic heart disease?
Answers are grounded in this paper and cite their sources.
Bay a 1040 demonstrates coronary and systemic vasodilatory properties and prevents anginal attacks in patients with ischemic heart disease.
A series of basic and clinical studies on a new anti-anginal agent, Bay a 1040, revealed the following facts. 1. With the artificial perfusion of a large branch of the coronary artery under a constant pressure head in closed-chest dogs, and with intracoronary injection as a bolus of 0.1ml, 1.0μg of Bay a 1040 produced a transient and minimal decrease in the mean coronary resistance to flow without any change in blood pressures. With 5μg/kg injected intravenously, the mean resistance to flow decreased in the coronary area that was not exposed to the circulating Bay a 1040. From these observations it is probable that Bay a 1040 produces a mild "active" coronary dilatation as well as "passive" coronary dilatation. 2. With 5μg/kg injected intravenously in open-chest dogs, the evoked circulatory change was that of transient dilatation of the systemic resistance vessels without any change in the capacitance of the circulatory system. 3. Middle-aged patients with ischemic heart disease responded to the oral administration of 20mg with "dilatation" of the systemic resistance vessels. Left ventricular external work and pressure-time-product were also diminished. 4. A clinical trial with cross-over design revealed an outstanding . "preventive" efficacy of this agent, as given in daily dose of 60mg in 3 divided portions, on the occurrence of anginal attacks in the patients with ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Hayase et al. (1971) conducted an RCT in Ischemic heart disease. Bay a 1040 was evaluated on Occurrence of anginal attacks. Bay a 1040 ( daily) demonstrated outstanding preventive efficacy on the occurrence of anginal attacks in patients with ischemic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: